Bupropion hydrobromide and therapeutic applications
View Patent ↗Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
1. A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
wherein administration of an amount of a bupropion hydrobromide to a first rat results in less incidences of and/or less severe bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
2. The composition of claim 1 , which is in tablet form.
3. The composition of claim 1 , which is a modified release formulation.
4. The composition of claim 1 , which is in tablet form and wherein the bupropion hydrobromide is contained within a core of the tablet further comprising a coating over the core.
5. The composition of claim 4 , wherein the coating is a controlled release coating.
6. A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
wherein administration of about 100 mg/kg of a bupropion hydrobromide to a first rat results in less incidences of and/or severity of bupropion-induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
7. A method of treating a subject at risk of bupropion-induced seizures in need of bupropion treatment, the method comprising:
administering a composition comprising bupropion hydrobromide to said subject in an amount sufficient to treat said subject.
8. The method of claim 7 , wherein the composition comprises an amount of bupropion hydrobromide chosen from 174 mg, 348 mg and 522 mg.
9. The method of claim 7 , wherein the composition is in tablet form and the administering comprises oral administration.
10. The method of claim 7 , wherein the composition is a modified release formulation.
11. The method of claim 7 , wherein the composition is in tablet form and wherein the bupropion hydrobromide is contained within a core of the tablet further comprising a coating over the core.
12. The method of claim 7 , wherein the coating is a controlled release coating.
13. A method of reducing incidences of bupropion-induced seizures comprising: administering a pharmaceutically effective amount of bupropion hydrobromide to a subject in need of bupropion administration;
wherein incidences of bupropion-induced seizures resulting from the administration of bupropion hydrobromide is less than incidences of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride.
14. The method of claim 13 wherein bupropion-induced seizures resulting from the administration of bupropion hydrobromide is less severe than bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride.
15. A method of reducing incidences of bupropion-induced seizures comprising:
administering a pharmaceutically effective amount of bupropion hydrobromide to a subject in need of bupropion administration;
wherein administration of about 100 mg/kg of the bupropion hydrobromide to a first rat results in less incidences of bupropion-induced seizures when compared to incidences of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of bupropion-induced seizures in the first and second rats are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.
16. A composition comprising bupropion hydrobromide and at least one pharmaceutically acceptable excipient;
wherein administration of about 100 mg/kg of a bupropion hydrobromide used to manufacture the composition to a first rat results in less incidences of and/or severity of bupropion induced seizures when compared to incidences of and/or severity of bupropion-induced seizures resulting from administration of an equivalent molar amount of bupropion hydrochloride to a second rat; and
wherein the incidences of and/or severity of bupropion-induced seizures are measured by an electroencephalogram analysis using a hippocampally implanted depth electrode.